Article Information
History
- February 14, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Fiona A Pearce1,2,3,
- Sean H Lim4,
- Mary Bythell3,
- Peter Lanyon1,2,3,
- Rachel Hogg5,
- Adam Taylor1,3,
- Gillian Powter6,
- Graham S Cooke7,
- Helen Ward7,8,
- Joseph Chilcot9,
- Helen Thomas5,
- Lisa Mumford5,
- Stephen P McAdoo10,11,
- Gavin J Pettigrew12,
- Liz Lightstone10,11 and
- Michelle Willicombe10,11,*
- 1Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK
- 2Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UK
- 3National Disease Registration Service, NHS Digital, Leeds, UK
- 4Centre for Cancer Immunology, University of Southampton, Southampton, UK
- 5Statistics and Clinical Research, NHS Blood and Transplant, Bristol, UK
- 6NHS Blood and Transplant Clinical Trials Unit, Oxford, UK
- 7Department of Infectious Disease, Imperial College London, London, UK
- 8School of Public Health, Imperial College London, London, UK
- 9Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK
- 10Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London, UK
- 11Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK
- 12Department of Surgery, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
- ↵*Corresponding author:
Dr Michelle Willicombe, Centre for Inflammatory Disease Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, W12 0NN, E-mail: m.willicombe08{at}imperial.ac.uk
Posted February 14, 2023.
Antibody prevalence after 3 or more COVID-19 vaccine doses in 23,000 immunosuppressed individuals: a cross-sectional study from MELODY
